Scroll back to top

£250k investment doubles capacity across many service areas

Manchester, UK, 28 November 2017: Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has invested £250k in new equipment at its East Kilbride analytical services site. This follows over £250k of new instrumentation which was added to the facility in 2016.

The investment has doubled capacity across many capabilities, including GC/MS (Gas Chromatography/Mass Spectrometry),GC/MS headspace (for analysis of volatile compounds), GCxGC (comprehensive two-dimensional gas chromatography), and metal and anion analysis, and forms part of a wider program to upgrade and add to systems, to better support customers’ testing requirements and provide faster turnaround times. Concept also plans to increase headcount at the site by 8 FTEs in order to support the increase in capacity and workload, in addition to the 7 FTEs that joined the team in 2017.

Darryl Chapman VP Sales and Marketing, Concept Life Sciences, said: “The recent investments in the East Kilbride site demonstrate Concept’s continued commitment to enhancing the customer experience, and to growing the business in Scotland. This latest investment brings Concept’s total investment into the Scottish economy in the last three years to in excess of £20 million, following the acquisition of businesses in Dundee and Edinburgh.”

About Concept Life Sciences
Concept Life Sciences provides integrated, high quality drug discovery, development and analytical services to the life science sector. Formed as a result of targeted acquisition and organic growth, the Company has the in-house expertise and resource to support customers with projects spanning from target discovery to the clinic, adding value and IP throughout the discovery pathway.

With a track record of delivering knowledge-based, science-led solutions, the Company employs over 700 FTEs, including more than 500 highly skilled, experienced scientists, supporting its global client base from 10 state of the art laboratory facilities.

Concept Life Sciences has worked with all of the top 10 pharma and biotech companies, and is targeting revenues exceeding $60m in 2017. Having experienced rapid growth, the Company remains focused on problem solving, quality, collaboration, and flexibility.

Concept Life Sciences was formed in 2014 with backing from private equity firm Equistone Partners Europe.